448 related articles for article (PubMed ID: 25933207)
21. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
[No Abstract] [Full Text] [Related]
22. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab.
Nahar KJ; Rawson RV; Ahmed T; Tattersall S; Sandanayake N; Kiely CJ; Lo S; Carlino M; Palendira U; Scolyer RA; Long GV; Menzies AM
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234603
[TBL] [Abstract][Full Text] [Related]
23. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
Wang Y; Abu-Sbeih H; Mao E; Ali N; Qiao W; Trinh VA; Zobniw C; Johnson DH; Samdani R; Lum P; Shuttlesworth G; Blechacz B; Bresalier R; Miller E; Thirumurthi S; Richards D; Raju G; Stroehlein J; Diab A
Inflamm Bowel Dis; 2018 Jul; 24(8):1695-1705. PubMed ID: 29718308
[TBL] [Abstract][Full Text] [Related]
24. The cost of ipilimumab toxicity: a single-centre analysis.
Yousaf N; Davidson M; Goode E; Thomas C; Hung R; Gore M; Larkin J
Melanoma Res; 2015 Jun; 25(3):259-64. PubMed ID: 25860328
[TBL] [Abstract][Full Text] [Related]
25. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.
Johnson DB; Friedman DL; Berry E; Decker I; Ye F; Zhao S; Morgans AK; Puzanov I; Sosman JA; Lovly CM
Cancer Immunol Res; 2015 May; 3(5):464-9. PubMed ID: 25649350
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis.
Franklin C; Rooms I; Fiedler M; Reis H; Milsch L; Herz S; Livingstone E; Zimmer L; Schmid KW; Dittmer U; Schadendorf D; Schilling B
Eur J Cancer; 2017 Nov; 86():248-256. PubMed ID: 29055840
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
Margolin K; Ernstoff MS; Hamid O; Lawrence D; McDermott D; Puzanov I; Wolchok JD; Clark JI; Sznol M; Logan TF; Richards J; Michener T; Balogh A; Heller KN; Hodi FS
Lancet Oncol; 2012 May; 13(5):459-65. PubMed ID: 22456429
[TBL] [Abstract][Full Text] [Related]
28. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson.
Wang Y; Abu-Sbeih H; Mao E; Ali N; Ali FS; Qiao W; Lum P; Raju G; Shuttlesworth G; Stroehlein J; Diab A
J Immunother Cancer; 2018 May; 6(1):37. PubMed ID: 29747688
[TBL] [Abstract][Full Text] [Related]
29. Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy.
Bamias G; Delladetsima I; Perdiki M; Siakavellas SI; Goukos D; Papatheodoridis GV; Daikos GL; Gogas H
Cancer Invest; 2017 Aug; 35(7):443-455. PubMed ID: 28548891
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
31. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.
Johnston RL; Lutzky J; Chodhry A; Barkin JS
Dig Dis Sci; 2009 Nov; 54(11):2538-40. PubMed ID: 19104936
[TBL] [Abstract][Full Text] [Related]
33. Ipilimumab-induced colitis on FDG PET/CT.
Lyall A; Vargas HA; Carvajal RD; Ulaner G
Clin Nucl Med; 2012 Jun; 37(6):629-30. PubMed ID: 22614208
[TBL] [Abstract][Full Text] [Related]
34. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
[TBL] [Abstract][Full Text] [Related]
35. Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
O'Kane GM; Lyons TG; Colleran GC; Ahmad MW; Alken S; Kavanagh EC; Fitzpatrick D; Murray B; Kelly CM
Oncol Res Treat; 2014; 37(12):757-60. PubMed ID: 25531722
[TBL] [Abstract][Full Text] [Related]
36. A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis.
Gaudy-Marqueste C; Monestier S; Franques J; Cantais E; Richard MA; Grob JJ
J Immunother; 2013 Jan; 36(1):77-8. PubMed ID: 23211620
[TBL] [Abstract][Full Text] [Related]
37. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
38. Infliximab for IPILIMUMAB-Related Colitis-Letter.
Arriola E; Wheater M; Karydis I; Thomas G; Ottensmeier C
Clin Cancer Res; 2015 Dec; 21(24):5642-3. PubMed ID: 26672088
[No Abstract] [Full Text] [Related]
39. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.
Weber JS; Amin A; Minor D; Siegel J; Berman D; O'Day SJ
Melanoma Res; 2011 Dec; 21(6):530-4. PubMed ID: 22051508
[TBL] [Abstract][Full Text] [Related]
40. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
